Your browser doesn't support javascript.
loading
F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.
Haslerud, Torjan; Brauckhoff, Katrin; Reisæter, Lars; Küfner Lein, Regina; Heinecke, Achim; Varhaug, Jan Erik; Biermann, Martin.
Afiliación
  • Haslerud T; Nuclear Medicine/PET-Center, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
  • Brauckhoff K; Section for Endocrine Surgery, Haukeland University Hospital, Bergen, Norway.
  • Reisæter L; Section for Oncological Imaging, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
  • Küfner Lein R; Medical and Dental Library, University of Bergen, Bergen/Norway.
  • Heinecke A; Institute of Biostatistics and Clinical Research, University of Münster, Münster/Germany.
  • Varhaug JE; Section for Oncological Imaging, Department of Radiology, Haukeland University Hospital, Bergen, Norway Department of Clinical Science, University of Bergen, Bergen/Norway.
  • Biermann M; Nuclear Medicine/PET-Center, Department of Radiology, Haukeland University Hospital, Bergen, Norway Department of Clinical Medicine, University of Bergen, Bergen/Norway martin.biermann@uib.no.
Acta Radiol ; 57(10): 1193-200, 2016 Oct.
Article en En | MEDLINE | ID: mdl-26163534
ABSTRACT

BACKGROUND:

Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC).

PURPOSE:

To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy. MATERIAL AND

METHODS:

A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance measures were pooled using Reitsma's bivariate model.

RESULTS:

Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity were 79.4% (95% confidence interval [CI], 73.9-84.1) and 79.4% (95% CI, 71.2-85.4), respectively, with an area under the curve of 0.858.

CONCLUSION:

F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative therapy.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Radiofármacos / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Acta Radiol Año: 2016 Tipo del documento: Article País de afiliación: Noruega
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Radiofármacos / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Acta Radiol Año: 2016 Tipo del documento: Article País de afiliación: Noruega